MRUS Projected Dividend Yield
Ord/Merus NV ( NASDAQ : MRUS )Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors. 20 YEAR PERFORMANCE RESULTS |
MRUS Dividend History Detail MRUS Dividend News MRUS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |